133 related articles for article (PubMed ID: 26248802)
1. Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.
Schuler AD; Engles CA; Maeda DY; Quinn MT; Kirpotina LN; Wicomb WN; Mason SN; Auten RL; Zebala JA
Bioorg Med Chem Lett; 2015 Sep; 25(18):3793-7. PubMed ID: 26248802
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Fan GH; Zebala JA
J Med Chem; 2014 Oct; 57(20):8378-97. PubMed ID: 25254640
[TBL] [Abstract][Full Text] [Related]
3. Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.
Maeda DY; Peck AM; Schuler AD; Quinn MT; Kirpotina LN; Wicomb WN; Auten RL; Gundla R; Zebala JA
Bioorg Med Chem Lett; 2015 Jun; 25(11):2280-4. PubMed ID: 25933594
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
6. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
[TBL] [Abstract][Full Text] [Related]
7. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
8. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
9. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
[TBL] [Abstract][Full Text] [Related]
10. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
[TBL] [Abstract][Full Text] [Related]
11. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
12. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
Busch-Petersen J
Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
[TBL] [Abstract][Full Text] [Related]
13. Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists.
Austin RP; Bennion C; Bonnert RV; Cheema L; Cook AR; Cox RJ; Ebden MR; Gaw A; Grime K; Meghani P; Nicholls D; Phillips C; Smith N; Steele J; Stonehouse JP
Bioorg Med Chem Lett; 2015 Apr; 25(7):1616-20. PubMed ID: 25708618
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
[TBL] [Abstract][Full Text] [Related]
15. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats.
Barsante MM; Cunha TM; Allegretti M; Cattani F; Policani F; Bizzarri C; Tafuri WL; Poole S; Cunha FQ; Bertini R; Teixeira MM
Br J Pharmacol; 2008 Mar; 153(5):992-1002. PubMed ID: 17891165
[TBL] [Abstract][Full Text] [Related]
17. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
18. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma.
Sharma B; Singh S; Varney ML; Singh RK
Expert Opin Ther Targets; 2010 Apr; 14(4):435-42. PubMed ID: 20230195
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor.
Hosoki K; Rajarathnam K; Sur S
Clin Exp Allergy; 2019 Jan; 49(1):130-132. PubMed ID: 30218547
[No Abstract] [Full Text] [Related]
20. Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism.
Maeda DY; Quinn MT; Schepetkin IA; Kirpotina LN; Zebala JA
J Pharmacol Exp Ther; 2010 Jan; 332(1):145-52. PubMed ID: 19779130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]